Skip Navigation

Mary-Ellen Taplin, MD

Medical Oncology

Make an Appointment
Watch Video


  • Chair, Executive Committee for Clinical Research
  • Director of Clinical Research, Lank Center for Genitourinary Oncology
  • Institute Physician
  • Professor of Medicine, Harvard Medical School


Clinical Interests

  • Bladder cancer
  • Clinical trials
  • Hormone and chemotherapy
  • Kidney cancer
  • Prostate cancer
  • Testis cancer

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-582-7221
  • Fax617-632-2165


Dr. Taplin received her MD in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center and an oncology-hematology fellowship at Beth Israel Hospital and Harvard Medical School.

Dr. Taplin was on staff in medical oncology-hematology as an assistant and then associate professor of medicine at the University of Massachusetts from 1993 to 2003, when she joined Dana-Farber Cancer Institute.

Board Certification:

  • Hematology, 1996
  • Internal Medicine, 1989
  • Medical Oncology, 1993


  • Beth Israel Deaconess Medical Center, Hematology/Oncology


  • University of Massachusetts Medical Center, Chief Medical Resident
  • University of Massachusetts Medical Center, Internal Medicine

Medical School:

  • University of Massachusetts Medical School

Recent Awards:

  • Dana-Farber Cancer Center Medical Oncology Teaching Award 2009


Since completing her Hematology-Oncology fellowship at Beth Israel Medical Center/Harvard Medical School in 1993, Dr. Mary-Ellen Taplin has dedicated herself to academic genitourinary (GU) oncology at the University of Massachusetts Medical Center (1993-2003) and Dana-Farber Cancer Institute (DFCI)/Harvard Medical School (2003-present). Dr. Taplin has assiduously focused on clinical and correlative investigations in prostate cancer while providing outstanding patient care, teaching and mentoring trainees and developing excellent administrative skills in clinical research management. She is a key opinion leader in GU oncology and has provided leadership in all phases of clinical trials. She was the principal investigator for the first biomarker (androgen receptor spice variant) directed trial (galeterone) in metastatic prostate cancer. Leadership on the phase 3 galeterone trial and her work with abiraterone and enzalutamide demonstrates the full circle of bench to bedside, as Dr. Taplin was the first to report androgen receptor mutations in metastatic prostate cancer samples in the New England Journal of Medicine in 1995. Her work has increased the understanding of mechanisms of prostate cancer response and resistance and remains important especially in the context of next generation hormone therapy in prostate cancer. Dr. Taplin’s dedication, clinical expertise and service together with her innovation and publication record supported her promotion to Professor of Medicine at Harvard Medical School in 2017.



Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1232C
Boston, MA 02215
Get Directions